Is Editas Medicine, Inc. overvalued or undervalued?

As of 30 March 2016, the valuation grade for Editas Medicine, Inc. has moved from does not qualify to risky. The company appears to be overvalued given its current financial metrics. The price-to-book value stands at 2.56, while the EV to EBITDA ratio is a mere 0.24, indicating significant concerns about profitability and valuation compared to its peers.
In comparison to its industry, Editas Medicine, Inc. shows a stark contrast with peers such as Novavax, Inc., which has a P/E ratio of 2.15, and Kura Oncology, Inc., with an EV to EBITDA of 0.54. The company's return on equity (ROE) is notably negative at -317.44%, which raises further red flags about its financial health. Additionally, while the stock has performed well year-to-date with a return of 65.35%, its long-term performance has been dismal, with a 5-year return of -93.88%, reinforcing the notion that the stock is currently overvalued.